CRBU SHAREHOLDER ALERT: Jakubowitz Law Reminds Caribou Shareholders of a Lead Plaintiff Deadline of April 11, 2023

NEW YORK, Feb. 24, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Caribou Biosciences, Inc. (NASDAQ: CRBU).

To receive updates on the lawsuit, fill out the form:
https://claimyourloss.com/securities/caribou-biosciences-inc-loss-submission-form/?id=36791&from=4

This lawsuit is on behalf of persons and entities that purchased or otherwise acquired: (a) Caribou common stock pursuant and/or traceable to documents issued in connection with the Company's initial public offering conducted on or about July 23, 2021; and/or (b) Caribou securities between July 23, 2021, and December 9, 2022.

Shareholders interested in acting as a lead plaintiff representing the class of wronged shareholders have until April 11, 2023 to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

According to a filed complaint, Caribou Biosciences, Inc. issued materially false and/or misleading statements and/or failed to disclose that:  (i) the treatment effect of the Company's product candidate, CB-010, was not as durable as defendants had led investors to believe; (ii) accordingly, CB-010's clinical and commercial prospects were overstated; and (iii) as a result, documents issued in connection with Caribou's initial public offer and defendants' public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (628) 895-0423
F: (212) 537-5887

SOURCE Jakubowitz Law

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED